Home / Stock ratings / CRL
Stock rating · Services-Commercial Physical & Biological Research
Charles River Laboratories International, Inc. (CRL) Stock Rating & Analysis
As of October 13, 2026, MELANY rates Charles River Laboratories International, Inc. 68 out of 100 (Favorable). Its highest factor score is catalyst setup at 89, and its lowest is business quality at 40.
MELANY ratingRated 2026-10-13CRL · composite score
About Charles River Laboratories International, Inc.
Charles River Laboratories, founded in 1947, is a leading provider of drug discovery and development services. Its research model and services segment is the leading provider of animal models for laboratory testing, breeding and delivering research models with specific genetic characteristics for preclinical studies worldwide. Its discovery and safety assessment segment covers the services needed to move a drug through early development, including discovery services.
Rating as of 2026-10-13 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
Why CRL scores 68/100
CRL's 8 factor scores run from 40 to 89, and 3 of them sit above its composite of 68. Here is how CRL breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- PEG ratio 0.12 (< 1 = undervalued)
Margins, returns on capital, and balance-sheet strength.
Direction and relative strength of the recent share-price trend.
- Price +4.6% above 50-day MA
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
- Earnings in 22 days (strong beat history)
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
- Earnings in 22 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How CRL compares
As of October 13, 2026, Charles River Laboratories International, Inc. ranks 1st of the 2 companies with a MELANY rating page in its SEC industry group (Services-Commercial Physical & Biological Research), where the average score is 66.
Key risks for CRL
- No positive trailing earnings, valuation cannot be anchored to current P/E
Sector and theme context
Charles River Laboratories International, Inc. sits in the Healthcare sector theme, which MELANY currently rates 62/100 for strength. Theme strength feeds CRL's momentum and catalyst factors above.
CRL trade plan (Pro)
MELANY has a full position plan for Charles River Laboratories International, Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates CRL
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Charles River Laboratories International, Inc.'s 68/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about CRL
Is Charles River Laboratories International, Inc. (CRL) a buy?
As of 2026-10-13, MELANY rated Charles River Laboratories International, Inc. Favorable with a composite score of 68/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Charles River Laboratories International, Inc.'s MELANY score?
Charles River Laboratories International, Inc. (CRL) has a MELANY composite score of 68/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the CRL stock rating calculated?
MELANY scores CRL from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Charles River Laboratories International, Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Charles River Laboratories International, Inc. (CRL) Favorable with a composite of 68/100 as of 2026-10-13. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the CRL stock price forecast?
MELANY does not publish price targets or forecasts for CRL. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 68/100 across eight factors for Charles River Laboratories International, Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is CRL stock overvalued or undervalued?
MELANY's valuation factor currently reads 61/100 for Charles River Laboratories International, Inc., where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives CRL's read.
What price should I buy CRL at?
Rather than chasing the current price, MELANY computes a smart entry zone for CRL: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying CRL stock?
The top risks MELANY currently flags for Charles River Laboratories International, Inc.: No positive trailing earnings, valuation cannot be anchored to current P/E. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Charles River Laboratories International, Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 40/100 for Charles River Laboratories International, Inc., and earnings track record, at 78/100. The 68/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will CRL stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 75/100 for CRL right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this CRL rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-13. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores CRL continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, CRL included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.